These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 36627880)

  • 1. [Not Available].
    Marcellusi A; Bini C; Rotundo MA; Arcangeli E; Martinez L; Vilela FS; Mennini FS
    Glob Reg Health Technol Assess; 2021; 8():155-167. PubMed ID: 36627880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of the increased risk associated with recurrent events or polyvascular atherosclerotic cardiovascular disease in the United Kingdom.
    Danese MD; Pemberton-Ross P; Catterick D; Villa G
    Eur J Prev Cardiol; 2021 Apr; 28(3):335-343. PubMed ID: 33891694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden.
    Landmesser U; Lindgren P; Hagström E; van Hout B; Villa G; Pemberton-Ross P; Arellano J; Svensson ME; Sibartie M; Fonarow GC
    Eur Heart J Qual Care Clin Outcomes; 2022 Jan; 8(1):31-38. PubMed ID: 33063111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia.
    Koren MJ; Sabatine MS; Giugliano RP; Langslet G; Wiviott SD; Ruzza A; Ma Y; Hamer AW; Wasserman SM; Raal FJ
    J Am Coll Cardiol; 2019 Oct; 74(17):2132-2146. PubMed ID: 31648705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
    Mach F; Baigent C; Catapano AL; Koskinas KC; Casula M; Badimon L; Chapman MJ; De Backer GG; Delgado V; Ference BA; Graham IM; Halliday A; Landmesser U; Mihaylova B; Pedersen TR; Riccardi G; Richter DJ; Sabatine MS; Taskinen MR; Tokgozoglu L; Wiklund O;
    Eur Heart J; 2020 Jan; 41(1):111-188. PubMed ID: 31504418
    [No Abstract]   [Full Text] [Related]  

  • 6. Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease.
    Fonarow GC; van Hout B; Villa G; Arellano J; Lindgren P
    JAMA Cardiol; 2019 Jul; 4(7):691-695. PubMed ID: 31166576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk.
    Cesaro A; Gragnano F; Fimiani F; Moscarella E; Diana V; Pariggiano I; Concilio C; Natale F; Limongelli G; Bossone E; Calabrò P
    Eur J Prev Cardiol; 2020 Mar; 27(5):556-558. PubMed ID: 30913901
    [No Abstract]   [Full Text] [Related]  

  • 8. Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data.
    Lindh M; Banefelt J; Fox KM; Hallberg S; Tai MH; Eriksson M; Villa G; Svensson MK; Qian Y
    Eur Heart J Qual Care Clin Outcomes; 2019 Jul; 5(3):225-232. PubMed ID: 30649251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review.
    Janković SM; Tešić D; Anđelković J; Kostić M
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):461-474. PubMed ID: 30014724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years.
    Borissov B; Urbich M; Georgieva B; Tsenov S; Villa G
    J Mark Access Health Policy; 2017; 5(1):1412753. PubMed ID: 29321830
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
    Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
    JAMA Cardiol; 2017 Oct; 2(10):1069-1078. PubMed ID: 28832867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
    Ference BA; Ginsberg HN; Graham I; Ray KK; Packard CJ; Bruckert E; Hegele RA; Krauss RM; Raal FJ; Schunkert H; Watts GF; Borén J; Fazio S; Horton JD; Masana L; Nicholls SJ; Nordestgaard BG; van de Sluis B; Taskinen MR; Tokgözoglu L; Landmesser U; Laufs U; Wiklund O; Stock JK; Chapman MJ; Catapano AL
    Eur Heart J; 2017 Aug; 38(32):2459-2472. PubMed ID: 28444290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
    Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV
    Clin Ther; 2017 Apr; 39(4):771-786.e3. PubMed ID: 28366593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.
    Benjamin EJ; Blaha MJ; Chiuve SE; Cushman M; Das SR; Deo R; de Ferranti SD; Floyd J; Fornage M; Gillespie C; Isasi CR; Jiménez MC; Jordan LC; Judd SE; Lackland D; Lichtman JH; Lisabeth L; Liu S; Longenecker CT; Mackey RH; Matsushita K; Mozaffarian D; Mussolino ME; Nasir K; Neumar RW; Palaniappan L; Pandey DK; Thiagarajan RR; Reeves MJ; Ritchey M; Rodriguez CJ; Roth GA; Rosamond WD; Sasson C; Towfighi A; Tsao CW; Turner MB; Virani SS; Voeks JH; Willey JZ; Wilkins JT; Wu JH; Alger HM; Wong SS; Muntner P;
    Circulation; 2017 Mar; 135(10):e146-e603. PubMed ID: 28122885
    [No Abstract]   [Full Text] [Related]  

  • 15. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.
    Toth PP; Danese M; Villa G; Qian Y; Beaubrun A; Lira A; Jansen JP
    J Med Econ; 2017 Jun; 20(6):555-564. PubMed ID: 28097904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.
    Ference BA; Robinson JG; Brook RD; Catapano AL; Chapman MJ; Neff DR; Voros S; Giugliano RP; Davey Smith G; Fazio S; Sabatine MS
    N Engl J Med; 2016 Dec; 375(22):2144-2153. PubMed ID: 27959767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.
    Landmesser U; Chapman MJ; Farnier M; Gencer B; Gielen S; Hovingh GK; Lüscher TF; Sinning D; Tokgözoglu L; Wiklund O; Zamorano JL; Pinto FJ; Catapano AL; ;
    Eur Heart J; 2017 Aug; 38(29):2245-2255. PubMed ID: 27789571
    [No Abstract]   [Full Text] [Related]  

  • 18. A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies.
    Wei CY; Quek RGW; Villa G; Gandra SR; Forbes CA; Ryder S; Armstrong N; Deshpande S; Duffy S; Kleijnen J; Lindgren P
    Pharmacoeconomics; 2017 Mar; 35(3):297-318. PubMed ID: 27785772
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.